LLY News and Press, Eli Lilly and Company From 02/02/24

2024-02-02 15:00:00 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...

2024-02-02 13:06:23 ET More on AbbVie AbbVie Q4 Earnings Preview: Few Clouds On Horizon Thanks To Masterful Management (Rating Upgrade) AbbVie Inc. (ABBV) JPMorgan 42nd Annual Healthcare Conference AbbVie: Still Expensive Despite The Great M&A Acumen AbbV...

2024-02-02 12:43:50 ET Summary Regeneron returned to topline growth in 2023 and this has led to the company's valuation rising to my expected EV/revenue range. The company is making significant investments in the obesity space, focusing on preserving lean mass and reducing fat mas...

2024-02-01 13:22:16 ET Short interest in healthcare stocks ticked higher from the end of 2023, with bets against healthcare provider and services ranking highest according to mid-January numbers. Read the full article on Seeking Alpha For further details see: Lilly, Zoetis, ...

2024-02-01 10:13:39 ET More on Bristol-Myers, Johnson & Johnson, etc. Pfizer Is Down 54% From Highs, Now Yields 6.1% Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value Pfizer: Reviewing Q4 Earnings, FY24 Guidance - Why I Disagree Wit...

2024-02-01 10:13:39 ET More on Bristol-Myers Squibb, Johnson & Johnson, etc. Pfizer Is Down 54% From Highs, Now Yields 6.1% Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value Pfizer: Reviewing Q4 Earnings, FY24 Guidance - Why I Disag...

2024-02-01 09:38:18 ET More on NeuroBo Pharmaceuticals Seeking Alpha’s Quant Rating on NeuroBo Pharmaceuticals Historical earnings data for NeuroBo Pharmaceuticals Financial information for NeuroBo Pharmaceuticals Read the full article on Seeking Alp...

2024-01-31 18:16:00 ET Eli Lilly (NYSE: LLY) stock eked out a gain on the stock market Wednesday, but the company doesn't necessarily have itself to thank for this. One of its rival pharmaceutical companies posted strong annual results fueled largely by a product category Lilly is e...

2024-01-31 13:25:01 ET Summary I forecast GLP-1 drugs to become the largest-selling pharmaceutical class, with US sales of $150 billion in 2030. GLP-1 agonists have shown favorable cardiovascular outcomes and beneficial effects on various organs, and in 2024 there will be data on ...

2024-01-31 12:32:57 ET More on Eli Lilly, Novo Nordisk, etc. Novo Nordisk A/S (NVO) Q4 2023 Earnings Call Transcript Biotech And Pharma Diversification Pays Off Novo Nordisk: Outlook For Weight Loss Drugs In 2024 Novo Nordisk stock hits all-time high as Wegov...